The application of genomic and proteomic technologies in predictive, preventive and personalized medicine

C. D. Collins, Sharad B Purohit, R. H. Podolsky, H. S. Zhao, D. Schatz, S. E. Eckenrode, P. Yang, D. Hopkins, A. Muir, M. Hoffman, Richard A McIndoe, M. Rewers, Jin-Xiong She

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The long asymptomatic period before the onset of chronic diseases offers good opportunities for disease prevention. Indeed, many chronic diseases may be preventable by avoiding those factors that trigger the disease process (primary prevention) or by use of therapy that modulates the disease process before the onset of clinical symptoms (secondary prevention). Accurate prediction is vital for disease prevention so that therapy can be given to those individuals who are most likely to develop the disease. The utility of predictive markers is dependent on three parameters, which must be carefully assessed: sensitivity, specificity and positive predictive value. Specificity is important if a biomarker is to be used to identify individuals either for counseling or for preventive therapy. However, a reciprocal relationship exists between sensitivity and specificity. Thus, successful biomarkers will be highly specific without sacrificing sensitivity. Unfortunately, biomarkers with ideal specificity and sensitivity are difficult to find for many diseases. One potential solution is to use the combinatorial power of a large number of biomarkers, each of which alone may not offer satisfactory specificity and sensitivity. Recent technological advances in genetics, genomics, proteomics, and bioinformatics offer a great opportunity for biomarker discovery. The newly identified biomarkers have the potential to bring increased accuracy in disease diagnosis and classification, as well as therapeutic monitoring. In this review, we will use type 1 diabetes (T1D) as an example, when appropriate, to discuss pertinent issues related to high throughput biomarker discovery.

Original languageEnglish (US)
Pages (from-to)258-267
Number of pages10
JournalVascular Pharmacology
Volume45
Issue number5
DOIs
StatePublished - Nov 1 2006

Fingerprint

Precision Medicine
Preventive Medicine
Proteomics
Biomarkers
Technology
Sensitivity and Specificity
Chronic Disease
Primary Prevention
Therapeutics
Secondary Prevention
Genomics
Computational Biology
Type 1 Diabetes Mellitus
Counseling

Keywords

  • Biomarkers
  • Gene expression profiling
  • Proteomics
  • Type 1 diabetes

ASJC Scopus subject areas

  • Physiology
  • Molecular Medicine
  • Pharmacology

Cite this

The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. / Collins, C. D.; Purohit, Sharad B; Podolsky, R. H.; Zhao, H. S.; Schatz, D.; Eckenrode, S. E.; Yang, P.; Hopkins, D.; Muir, A.; Hoffman, M.; McIndoe, Richard A; Rewers, M.; She, Jin-Xiong.

In: Vascular Pharmacology, Vol. 45, No. 5, 01.11.2006, p. 258-267.

Research output: Contribution to journalArticle

Collins, CD, Purohit, SB, Podolsky, RH, Zhao, HS, Schatz, D, Eckenrode, SE, Yang, P, Hopkins, D, Muir, A, Hoffman, M, McIndoe, RA, Rewers, M & She, J-X 2006, 'The application of genomic and proteomic technologies in predictive, preventive and personalized medicine', Vascular Pharmacology, vol. 45, no. 5, pp. 258-267. https://doi.org/10.1016/j.vph.2006.08.003
Collins, C. D. ; Purohit, Sharad B ; Podolsky, R. H. ; Zhao, H. S. ; Schatz, D. ; Eckenrode, S. E. ; Yang, P. ; Hopkins, D. ; Muir, A. ; Hoffman, M. ; McIndoe, Richard A ; Rewers, M. ; She, Jin-Xiong. / The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. In: Vascular Pharmacology. 2006 ; Vol. 45, No. 5. pp. 258-267.
@article{24ebe8b2d6244555820c26377ed29732,
title = "The application of genomic and proteomic technologies in predictive, preventive and personalized medicine",
abstract = "The long asymptomatic period before the onset of chronic diseases offers good opportunities for disease prevention. Indeed, many chronic diseases may be preventable by avoiding those factors that trigger the disease process (primary prevention) or by use of therapy that modulates the disease process before the onset of clinical symptoms (secondary prevention). Accurate prediction is vital for disease prevention so that therapy can be given to those individuals who are most likely to develop the disease. The utility of predictive markers is dependent on three parameters, which must be carefully assessed: sensitivity, specificity and positive predictive value. Specificity is important if a biomarker is to be used to identify individuals either for counseling or for preventive therapy. However, a reciprocal relationship exists between sensitivity and specificity. Thus, successful biomarkers will be highly specific without sacrificing sensitivity. Unfortunately, biomarkers with ideal specificity and sensitivity are difficult to find for many diseases. One potential solution is to use the combinatorial power of a large number of biomarkers, each of which alone may not offer satisfactory specificity and sensitivity. Recent technological advances in genetics, genomics, proteomics, and bioinformatics offer a great opportunity for biomarker discovery. The newly identified biomarkers have the potential to bring increased accuracy in disease diagnosis and classification, as well as therapeutic monitoring. In this review, we will use type 1 diabetes (T1D) as an example, when appropriate, to discuss pertinent issues related to high throughput biomarker discovery.",
keywords = "Biomarkers, Gene expression profiling, Proteomics, Type 1 diabetes",
author = "Collins, {C. D.} and Purohit, {Sharad B} and Podolsky, {R. H.} and Zhao, {H. S.} and D. Schatz and Eckenrode, {S. E.} and P. Yang and D. Hopkins and A. Muir and M. Hoffman and McIndoe, {Richard A} and M. Rewers and Jin-Xiong She",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.vph.2006.08.003",
language = "English (US)",
volume = "45",
pages = "258--267",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The application of genomic and proteomic technologies in predictive, preventive and personalized medicine

AU - Collins, C. D.

AU - Purohit, Sharad B

AU - Podolsky, R. H.

AU - Zhao, H. S.

AU - Schatz, D.

AU - Eckenrode, S. E.

AU - Yang, P.

AU - Hopkins, D.

AU - Muir, A.

AU - Hoffman, M.

AU - McIndoe, Richard A

AU - Rewers, M.

AU - She, Jin-Xiong

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The long asymptomatic period before the onset of chronic diseases offers good opportunities for disease prevention. Indeed, many chronic diseases may be preventable by avoiding those factors that trigger the disease process (primary prevention) or by use of therapy that modulates the disease process before the onset of clinical symptoms (secondary prevention). Accurate prediction is vital for disease prevention so that therapy can be given to those individuals who are most likely to develop the disease. The utility of predictive markers is dependent on three parameters, which must be carefully assessed: sensitivity, specificity and positive predictive value. Specificity is important if a biomarker is to be used to identify individuals either for counseling or for preventive therapy. However, a reciprocal relationship exists between sensitivity and specificity. Thus, successful biomarkers will be highly specific without sacrificing sensitivity. Unfortunately, biomarkers with ideal specificity and sensitivity are difficult to find for many diseases. One potential solution is to use the combinatorial power of a large number of biomarkers, each of which alone may not offer satisfactory specificity and sensitivity. Recent technological advances in genetics, genomics, proteomics, and bioinformatics offer a great opportunity for biomarker discovery. The newly identified biomarkers have the potential to bring increased accuracy in disease diagnosis and classification, as well as therapeutic monitoring. In this review, we will use type 1 diabetes (T1D) as an example, when appropriate, to discuss pertinent issues related to high throughput biomarker discovery.

AB - The long asymptomatic period before the onset of chronic diseases offers good opportunities for disease prevention. Indeed, many chronic diseases may be preventable by avoiding those factors that trigger the disease process (primary prevention) or by use of therapy that modulates the disease process before the onset of clinical symptoms (secondary prevention). Accurate prediction is vital for disease prevention so that therapy can be given to those individuals who are most likely to develop the disease. The utility of predictive markers is dependent on three parameters, which must be carefully assessed: sensitivity, specificity and positive predictive value. Specificity is important if a biomarker is to be used to identify individuals either for counseling or for preventive therapy. However, a reciprocal relationship exists between sensitivity and specificity. Thus, successful biomarkers will be highly specific without sacrificing sensitivity. Unfortunately, biomarkers with ideal specificity and sensitivity are difficult to find for many diseases. One potential solution is to use the combinatorial power of a large number of biomarkers, each of which alone may not offer satisfactory specificity and sensitivity. Recent technological advances in genetics, genomics, proteomics, and bioinformatics offer a great opportunity for biomarker discovery. The newly identified biomarkers have the potential to bring increased accuracy in disease diagnosis and classification, as well as therapeutic monitoring. In this review, we will use type 1 diabetes (T1D) as an example, when appropriate, to discuss pertinent issues related to high throughput biomarker discovery.

KW - Biomarkers

KW - Gene expression profiling

KW - Proteomics

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33751099342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751099342&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2006.08.003

DO - 10.1016/j.vph.2006.08.003

M3 - Article

C2 - 17030152

AN - SCOPUS:33751099342

VL - 45

SP - 258

EP - 267

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 5

ER -